PRZOOM - /newswire/ -
Paris, Ile-de-France, France, 2011/03/09 - BMSystems & The Max Planck Institute of Psychiatry in Munich co-publish in Pharmaco-Psychiatry a new analytical paradigm, for the identification of “targeted pertinent biomarkers” in psychiatric disorders.
Dr. François Iris, BMSystems, and Prof. Chris W. Turck, the Max Planck Institute of Psychiatry, co-publish a reference article “Proteome-Based Pathway Modelling of Psychiatric Disorders” that describes a new analytical paradigm to definitively move research from “plethoric statistical biomarkers” to “targeted pertinent biomarkers” identification, exploiting a very strict synergic combination of Dynamic Quantitative Proteomic outputs with BMSystems’ unique CADI™ heuristic modeling.
We invite you to visit our new website and to download the publication
Beyond this publication, this new analytical paradigm will be presented at the 19th European Congress of Psychiatry: Vienna, Austria, 12-15 March 2011, organised by the European Psychiatric Association (EPA), the largest international association of psychiatrists in Europe. Dr. François IRIS is invited to present: "Methodology of Mapping in Integrative Molecular Biology associated to psychiatric and cognitive disorders".
This very productive research collaboration, started in 2008 with the publication of BioMarkers for Psychiatric Disorders, represent for both parties a strong potential for medical innovations and value creation.
Being the first, and to date, the only company that succeeded to create validated in-silico heuristic models of complex human pathologies and physiological processes, we offer to pharma companies the possibility to generate new & pertinent hypotheses, stop in time existing programs and launch lower risks, novel therapeutics programs without being obliged to change their existing R&D discovery processes.
Created in 2004, and profitable since 2006, we designed a unique heuristic systems biology business offer to provide all our partners and clients with a simplified results-oriented research paradigm that alleviates global R&D/business issues.
Because we do not sell our technologies, but deliver their outputs in open formats, our clients are not dependent upon external proprietary technologies to maintain and update these new & pertinent hypotheses.
Because clients' proprietary data protection is critical, we do not use their proprietary data to generate the first version of a CADI model, and we limit data transfers to experimentations results only during the CADI model’s validation phase.
If you are interested to learn more about our recent achievements and possible collaborations in the fields of neurodegenerative diseases, psychiatric and cognitive disorders, infectious diseases and cancer we shall be happy to meet your company’s representatives at Bio in Washington, June 27-30, 2011.
Manuel Gea, Co-founder & CEO
BIO-MODELING SYSTEMS Predictive Integrative Biology